Öz

Objective: This study aimed to evaluate the use of bivalirudin as an alternative to conventional anticoagulant therapy with heparin in patients requiring venovenous extracorporeal membrane oxygenation (V-V ECMO) support for Acute Respiratory Distress Syndrome (ARDS), with a focus on dose titration, therapeutic range monitoring, complications, and clinical outcomes.

Materials and Methods: This retrospective case series included six patients who received V-V ECMO support and systemic anticoagulation with bivalirudin between August 2021 and April 2022 at Sakarya University Training and Research Hospital due to a diagnosis of ARDS. Activated clotting time (ACT), activated partial thromboplastin time (aPTT), daily bivalirudin infusion doses, ECMO-related complications, and clinical outcomes were retrospectively analyzed.

Results: Bivalirudin infusion doses ranged between 0.01 and 0.2 mg/kg/h across all patients. ACT values were maintained within the target range in all cases, while aPTT values remained below target in four patients. Hemorrhagic complications were observed in two patients, while thrombotic events occurred in another two. In one patient, bivalirudin infusion was discontinued due to the development of acute kidney injury. Of the six patients, two were discharged, while four died during follow-up.

Conclusion: Bivalirudin appears to be a safe and effective alternative anticoagulant agent for patients undergoing V-V ECMO. However, individualized and meticulous anticoagulation monitoring is essential, particularly in the context of renal dysfunction, the strengths and limitations of aPTT and ACT monitoring, and the delicate balance between hemorrhagic and thrombotic risks.

Anahtar Kelimeler: Bivalirudin, ECMO, COVID-19, anticoagulation, aPTT, ACT, ARDS

Referanslar

  1. Klok FA, Kruip MJ, van der Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7. https://doi.org/10.1016/j.thromres.2020.04.013
  2. Shekar K, Badulak J, Peek G, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. ASAIO J. 2020;66:707-721. https://doi.org/10.1097/MAT.0000000000001193
  3. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7. https://doi.org/10.1111/jth.14768
  4. Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med. 2013;14:e77-84. https://doi.org/10.1097/PCC.0b013e31827127e4
  5. Brogan T, Lequier L, Lorusso R, MacLaren G, Peek G, editors. Extracorporeal life support: the ELSO red book. 5th ed. Extracorporeal Life Support Organization (ELSO); 2017.
  6. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710-5. https://doi.org/10.1182/blood-2005-04-1546
  7. Tong Y, Rouzhahong J, Zhou W, et al. Comparison of bivalirudin versus heparin in adult extracorporeal membrane oxygenation anticoagulant therapy: a retrospective case-control study. Int J Artif Organs. 2023;46:162-70. https://doi.org/10.1177/03913988221148763
  8. Rivosecchi RM, Arakelians AR, Ryan J, et al. Comparison of anticoagulation strategies in patients requiring venovenous extracorporeal membrane oxygenation: heparin versus bivalirudin. Crit Care Med. 2021;49:1129-36. https://doi.org/10.1097/CCM.0000000000004944
  9. Netley J, Roy J, Greenlee J, Hart S, Todt M, Statz B. Bivalirudin anticoagulation dosing protocol for extracorporeal membrane oxygenation: a retrospective review. J Extra Corpor Technol. 2018;50:161-6.
  10. Esper SA, Welsby IJ, Subramaniam K, et al. Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. Vox Sang. 2017;112:443-52. https://doi.org/10.1111/vox.12514
  11. Seelhammer TG, Rowse P, Yalamuri S. Bivalirudin for maintenance anticoagulation during venovenous extracorporeal membrane oxygenation for COVID-19. J Cardiothorac Vasc Anesth. 2021;35:1149-53. https://doi.org/10.1053/j.jvca.2020.06.059
  12. Hamzah M, Jarden AM, Ezetendu C, Stewart R. Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2020;21:827-34. https://doi.org/10.1097/PCC.0000000000002384
  13. Sheridan EA, Sekela ME, Pandya KA, Schadler A, Ather A. Comparison of bivalirudin versus unfractionated heparin for anticoagulation in adult patients on extracorporeal membrane oxygenation. ASAIO J. 2022;68:920-4. https://doi.org/10.1097/MAT.0000000000001598
  14. Kennedy DM, Alaniz C. Apparent argatroban resistance in a patient with elevated factor VIII levels. Ann Pharmacother. 2013;47:e29. https://doi.org/10.1345/aph.1R745
  15. McMichael AB, Ryerson LM, Ratano D, Fan E, Faraoni D, Annich GM. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2022;68:303-10. https://doi.org/10.1097/MAT.0000000000001652
  16. Ljajikj E, Zittermann A, Morshuis M, et al. Bivalirudin anticoagulation for left ventricular assist device implantation on an extracorporeal life support system in patients with heparin-induced thrombocytopenia antibodies. Interact Cardiovasc Thorac Surg. 2017;25:898-904. https://doi.org/10.1093/icvts/ivx251
  17. Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost. 2017;43:270-6. https://doi.org/10.1055/s-0036-1597297
  18. Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003;92:919-23. https://doi.org/10.1016/s0002-9149(03)00970-6
  19. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000;12 Suppl F:33F-6.
  20. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002;71:433-9. https://doi.org/10.1067/mcp.2002.124522
  21. Badulak J, Antonini MV, Stead CM, et al. Extracorporeal membrane oxygenation for COVID-19: updated 2021 guidelines from the extracorporeal life support organization. ASAIO J. 2021;67:485-95. https://doi.org/10.1097/MAT.0000000000001422
  22. Roedl K, Kahn A, Jarczak D, et al. Clinical characteristics, complications and outcomes of patients with severe acute respiratory distress syndrome related to COVID-19 or influenza requiring extracorporeal membrane oxygenation-A retrospective cohort study. J Clin Med. 2021;10:5440. https://doi.org/10.3390/jcm10225440
  23. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995-2002. https://doi.org/10.1111/jth.14888
  24. Arachchillage DJ, Rajakaruna I, Scott I, et al. Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. Br J Haematol. 2022;196:566-76. https://doi.org/10.1111/bjh.17870
  25. Shaefi S, Brenner SK, Gupta S, et al. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Med. 2021;47:208-21. https://doi.org/10.1007/s00134-020-06331-9
  26. Li MJ, Shi JY, Zhang JH. Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: a meta-analysis. Br J Clin Pharmacol. 2022;88:2605-16. https://doi.org/10.1111/bcp.15251
  27. Yılmaz R, Arslan M , Özel Bilgi D, Çukurova Z. Should I change anticoagulane in veno-venous ECMO? Turk J Anaesthesiol Reanim. 2025;53:170-176. https://doi.org/10.4274/TJAR.2025.241745
  28. Ranucci M, Ballotta A, Kandil H, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15:R275. https://doi.org/10.1186/cc10556
  29. Halawi H, Harris JE, Goodarzi A, et al. Use of bivalirudin after initial heparin management among adult patients on long-term venovenous extracorporeal support as a bridge to lung transplant: a case series. Pharmacotherapy. 2024;44:283-9. https://doi.org/10.1002/phar.2910
  30. Taylor T, Campbell CT, Kelly B. A review of bivalirudin for pediatric and adult mechanical circulatory support. Am J Cardiovasc Drugs. 2021;21:395-409. https://doi.org/10.1007/s40256-020-00450-w
  31. Macielak S, Burcham P, Whitson B, Abdel-Rasoul M, Rozycki A. Impact of anticoagulation strategy and agents on extracorporeal membrane oxygenation therapy. Perfusion. 2019;34:671-8. https://doi.org/10.1177/0267659119842809

Telif hakkı ve lisans

Telif hakkı © 2026 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Attribution License (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır?

1.
Kuzgun Ö, Özmen Suner K, Toptan F, Küçük MG, Erdem AF. Use of bivalirudin in patients during veno-venous extracorporeal membrane oxygenation: a case series. Turk J Intensive Care. 2026;24(3):216-225. https://doi.org/10.63729/TJIC.2026.706